Dendritic cell-based vaccines and therapies for cancer
- 1 December 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 2 (8) , 919-928
- https://doi.org/10.1517/14712598.2.8.919
Abstract
Dendritic cells (DCs) are the most potent professional antigen-presenting cells (APCs), and are capable of stimulating naive T cells and driving primary immune responses. Due to this unique property, DCs represent both vectors and targets for immunological intervention in numerous diseases and are optimal candidates for vaccination protocols in cancer. This review provides an overview of DC immunobiology and the integration of these important APCs in immunotherapies for cancer.Keywords
This publication has 69 references indexed in Scilit:
- The Endoplasmic Reticulum-resident Heat Shock Protein Gp96 Activates Dendritic Cells via the Toll-like Receptor 2/4 PathwayJournal of Biological Chemistry, 2002
- CD91 Is a Common Receptor for Heat Shock Proteins gp96, hsp90, hsp70, and CalreticulinImmunity, 2001
- Immunobiology of Dendritic CellsAnnual Review of Immunology, 2000
- Dendritic Cells: A Link Between Innate and Adaptive ImmunityJournal of Clinical Immunology, 1999
- Dendritic CellsPublished by Elsevier ,1999
- The linkage between T‐cell and dendritic cell development in the mouse thymusImmunological Reviews, 1998
- Dendritic cells and the control of immunityNature, 1998
- Origin, maturation and antigen presenting function of dendritic cellsCurrent Opinion in Immunology, 1997
- Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.The Journal of Experimental Medicine, 1995
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991